Figure 1.

Forrest plot of the prognostic role of zoledronic acid administration versus placebo. A nonsignificant greater survival benefit overall in favor of zoledronic acid was observed. Analyses according to patients' baseline parathyroid hormone (PTH) status revealed opposite trends—a nonsignificant lower risk for death was seen in patients receiving zoledronic acid, compared with placebo, among those with a normal serum PTH level, and a nonsignificant greater risk for death was seen in patients with supranormal baseline PTH levels (test of homogeneity, p = .040).